LXRX vs NVCT: stock comparison and AI forecast
Lexicon Pharmaceuticals, Inc. (LXRX) and Nuvectis Pharma, Inc. (NVCT) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
LXRX Lexicon Pharmaceuticals, Inc.
- Market Cap
- $641M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
NVCT Nuvectis Pharma, Inc.
- Price
- $19.18 +115.7% · 6M
- Market Cap
- $625M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- LXRX and NVCT have similar market capitalizations ($641M and $625M).
- NVCT carries 1.46 times debt per unit of equity, against 0.43 times for LXRX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | LXRX | NVCT |
|---|---|---|
| Market Cap | $641M | $625M |
| P/B Ratio | 3.67x | 68.81x |
| EPS | $-0.22 | $-1.32 |
| Book Value/Share | $0.39 | $0.28 |
| Revenue/Share | $0.09 | – |
Profitability & Margins
| Metric | LXRX | NVCT |
|---|---|---|
| ROE | -35.0% | -306.6% |
| ROA | -24.4% | -124.5% |
| ROIC | -23.2% | – |
| Operating Margin | -131.4% | – |
| Net Margin | -147.4% | – |
| EBT Margin | -129.0% | – |
Financial Health
| Metric | LXRX | NVCT |
|---|---|---|
| Current Ratio | 13.37x | 1.68x |
| Quick Ratio | 13.29x | – |
| D/E Ratio | 0.43x | 1.46x |
| Financial Leverage | 1.43x | 2.46x |
| Interest Coverage | -23.5x | – |
| Working Capital | $182M | $9M |
Cash Flow
| Metric | LXRX | NVCT |
|---|---|---|
| Operating Cash Flow | -$65M | -$20M |
Operational Efficiency
| Metric | LXRX | NVCT |
|---|---|---|
| Asset Turnover | 0.17x | – |
| Receivables Turnover | 25.2x | – |
| Inventory Turnover | 0.3x | – |
| Fixed Assets Turnover | 25.1x | – |
| Days Sales Outstanding | 14 days | – |
| Days Inventory | 1219 days | – |
| Payables Period | 2389 days | – |
| Cash Conversion Cycle | -1155 days | – |
Income Statement
| Metric | LXRX | NVCT |
|---|---|---|
| Total Revenue | $41M | – |
| Operating Income | -$54M | -$29M |
| Net Income | -$61M | -$28M |
| R&D Expense | $60M | $20M |
| SG&A Expense | $35M | – |
| Cost of Goods Sold | $360K | – |
Dividend & Shareholder Information
| Metric | LXRX | NVCT |
|---|---|---|
| Shares Outstanding | 445M | 33M |
LXRX vs NVCT: stock comparison and AI forecast
Which is bigger, LXRX or NVCT?
LXRX and NVCT have similar market capitalizations ($641M and $625M).
Which one does Intratio's AI model rank higher, LXRX or NVCT?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.